Palatin Technologies (PTN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PTN · Stock Price

USD 18.90-2.55 (-11.89%)

Market Cap: $32.3M

Historical price data

Market Cap: $32.3MPipeline: 11 drugs (3 Phase 3)HQ: United States

Sector Ranking#312 in Small Molecule Drugs

Overview

Palatin Technologies is a clinical-stage biopharmaceutical company leveraging its proprietary Melanocortin Receptor Platform to develop targeted therapeutics for inflammatory, autoimmune, and metabolic conditions. Its lead programs focus on MC4R agonists for obesity, particularly rare neuroendocrine disorders like hypothalamic obesity and Prader-Willi syndrome, representing a paradigm shift from broad immunosuppression to targeted resolution. Recent achievements include a strategic collaboration with Boehringer Ingelheim in retinal diseases and positive preclinical data for an oral obesity candidate, though the company operates as a pre-revenue entity navigating clinical development and financing risks.

ObesityInflammatory DiseasesAutoimmune ConditionsRetinal Diseases

Technology Platform

Proprietary Melanocortin Receptor (MCR) Platform focused on designing selective peptide and small molecule agonists for specific melanocortin receptors (MC1R-MC5R) to modulate inflammation, immune response, and metabolism.

Pipeline

11

11 drugs in pipeline3 in Phase 3

Drug	Indication	Stage
Bremelanotide + Placebo	Hypoactive Sexual Desire Disorder	Phase 3
Vehicle Ophthalmic Solution + PL9643 Ophthalmic Solution	Dry Eye	Phase 3
Bremelanotide	Hypoactive Sexual Desire Disorder	Phase 3
PL8177 Placebo + PL8177	Ulcerative Colitis	Phase 2
Bremelanotide + RAAS inhibition therapy	Kidney Disease	Phase 2

Funding History

2

Total raised:$40M

Debt$15MLincoln Park CapitalMar 15, 2022

PIPE$25MUndisclosedSep 15, 2020

Opportunities

The global obesity drug market represents a >$100 billion opportunity, with Palatin's focused approach on rare neuroendocrine disorders like hypothalamic obesity providing a potential accelerated pathway.

The melanocortin platform's versatility also offers expansion into large inflammatory markets, validated by the strategic collaboration with Boehringer Ingelheim in retinal diseases.

Risk Factors

Palatin faces high clinical development risk with its novel candidates, significant financial and liquidity risk as a pre-revenue micro-cap company reliant on dilutive financing, and intense competition in both obesity and inflammation from well-resourced pharmaceutical companies with advanced pipelines.

Competitive Landscape

In obesity, Palatin competes directly with Rhythm Pharmaceuticals' approved MC4R agonist setmelanotide and the dominant GLP-1-based therapies from Novo Nordisk and Eli Lilly. In retinal diseases, its partner Boehringer Ingelheim will face entrenched anti-VEGF market leaders. Palatin's differentiation hinges on developing next-generation, selective melanocortin agonists with improved profiles.